Despite clinical evidence that thyroid hormone is essential for brain development before birth, effects of thyroid hormone on the fetal brain have been largely unexplored. One mechanism of thyroid hormone action is regulation of gene expression, because thyroid hormone receptors (TRs) are ligand-activated transcription factors. We used differential display to identify genes affected by acute T 4 administration to the dam before the onset of fetal thyroid function. Eight of the 11 genes that we identified were selectively expressed in brain areas known to contain TRs, indicating that these genes were directly regulated by thyroid hormone. Using in situ hybridization, we confirmed that the cortical expression of both neuroendocrine-specific protein (NSP) and Oct-1 was affected by changes in maternal thyroid status. Additionally, we demonstrated that both NSP and Oct-1 were expressed in the adult brain and that their responsiveness to thyroid hormone was retained. These data are the first to identify thyroid hormone-responsive genes in the fetal brain.
It is well known that thyroid hormone is essential for normal mammalian brain development (Oppenheimer and Schwartz, 1997) . However, until recently it was generally believed that the effects of thyroid hormone on brain development occur only after birth (Fisher, 1999) . Several recent clinical observations provide evidence to the contrary. First, thyroid hormone of maternal origin crosses the placenta and reaches the fetus (Vulsma et al., 1989; Contempre et al., 1993) . In addition, the receptors for thyroid hormone (TRs) are expressed in the fetal brain before the onset of fetal thyroid function, and receptor occupancy is within the range known to elicit physiological effects (Bernal and Pekonen, 1984; Ferreiro et al., 1988) . Second, iodine therapy prevents neurological cretinism in regions of endemic goiter only if initiated before the beginning of the third trimester (Cao et al., 1994) . Moreover, children born to pregnant women with untreated hypothyroidism during the second trimester exhibit measurable neurological deficits despite normal circulating thyroid hormone at birth (Haddow et al., 1999; Pop et al., 1999) . These findings strongly suggest that thyroid hormone, perhaps of maternal origin, plays important roles in brain development before birth.
The present study was initiated to test the broad hypothesis that thyroid hormone of maternal origin can exert direct effects on brain development before birth. Our strategy for testing this hypothesis was based on the recognition that thyroid hormone of maternal origin can reach the rat fetus (Obregon et al., 1984; Porterfield and Hendrich, 1992) and that TRs are expressed in the fetal rat brain before the onset of fetal thyroid function (Perez-Castillo et al., 1985; Bradley et al., 1992; Falcone et al., 1994) . Therefore, considering that TRs are ligand-activated transcription factors (Lazar, 1993 (Lazar, , 1994 Mangelsdorf and Evans, 1995) , we predicted that thyroid hormone of maternal origin can affect fetal brain development by regulating the expression of specific genes.
The classes of genes regulated by thyroid hormone in the fetal brain were difficult to predict because thyroid hormone is known to influence many cellular and developmental processes in the postnatal brain (Dussault and Ruel, 1987) , and the classes of genes supporting these processes may be widely varied. Therefore, we used the nonbiased method of differential display (Liang and Pardee, 1992) to identify putative thyroid hormoneresponsive genes in the fetal cortex. To ensure that we identified genes regulated by thyroid hormone of maternal origin, we focused on the period of fetal development before the onset of fetal thyroid function (Fisher et al., 1977) .
We now report the identification of several putative thyroid hormone-responsive genes that are selectively expressed in areas of the fetal brain that also express TRs. In addition, we have further characterized the response to thyroid hormone of two of these genes, one encoding neuroendocrine-specific protein (NSP) and one encoding Oct-1, in both the fetal and adult cortex.
MATERIALS AND METHODS
Animals. All animal procedures were performed in accordance with the National Institutes of Health Guidelines for animal research and were approved by the University of Massachusetts-Amherst Institutional Animal C are and Use Committee.
E xperiment I: Identification of thyroid hormone-responsive genes in the fetal corte x using differential display. Nulliparous female Sprague Dawley rats (n ϭ 10; Charles River, Wilmington, M A) were surgically thyroidectomized, provided with 0.1% calcium chloride in the drinking water (Z oeller et al., 1988) , and maintained on normal rat chow. T wo weeks after thyroidectomy, the females were paired with males overnight; the presence of sperm in a vaginal smear the following morning indicated mating, and this day was considered gestational day (GD) 1. Dams were given subcutaneous injections of either thyroxine [T 4 ; 1.25 g /100 gm body weight (BW); Sigma, St. L ouis, MO] or saline at 9 A.M. and 4 P.M. on GD15. At 9 A.M. on GD16, dams were decapitated, and trunk blood was collected for measurement of serum T 4 . Half of the fetuses from each litter were frozen intact on pulverized dry ice and stored at Ϫ80°C. Parasagittal sections of these GD16 fetuses were later collected for in situ hybridization. The cortex was dissected from the remaining fetuses, frozen on pulverized dry ice, and stored at Ϫ80°C until extraction of RNA.
Total RNA was isolated from the cortex of one GD16 fetus obtained from a dam with undetectable circulating total T 4 and from the cortex of one GD16 fetus from a dam with normal levels of total T 4 (23.1 ng /ml). Total RNA was extracted using an acid-phenol extraction procedure (Chomczynski and Sacchi, 1987) . This RNA was subjected to reverse transcription (RT) and amplified by RT-PCR according to the manufacturer's instructions (RNAimage, GenHunter, Nashville, TN). The PCR products amplified from each RNA pool using 16 primer pair combinations were electrophoresed in adjacent lanes on a 6% denaturing polyacrylamide gel. The gel was dried and apposed overnight to BioMax autoradiographic film (Kodak, Rochester, N Y) . Gene fragments that on film appeared to be either upregulated or downregulated by T 4 injection were extracted from the gel, reamplified, and cloned into pCRII (InVitrogen, C arlsbad, CA) or pBluescript K S (Stratagene, La Jolla, CA) (Table 1) . Sequencing was performed using ABI FS-Dye-Terminator chemistry (PE Applied Biosystems, Foster C ity, CA).
E xperiment II: Verification of thyroid hormone-responsive genes in the fetal brain. Nulliparous female Sprague Dawley rats (n ϭ 44; Z ivic Miller, Pottersville, PA) were exposed to the goitrogen 2-mercapto-1-methylimidazole (MM I; Sigma; n ϭ 23) to block the synthesis of thyroid hormone. MM I was dissolved to 0.02% in drinking water and provided fresh daily. Controls (n ϭ 21) were provided with unaltered drinking water. After 2 weeks of MM I treatment, the females were mated as described above. Both hypothyroid (MM I-treated) dams and euthyroid controls (no MM I) were subdivided into five additional groups receiving either no injection or a single subcutaneous injection of T 4 (1.25 g /100 gm BW; Sigma) at either 9 A.M. or 9 P.M. on either GD14 or GD15. These injections were therefore timed to occur 48, 36, 24, or 12 hr before animals were killed at 9 A.M. on GD16. At 9 A.M. on GD16, all dams were decapitated, and trunk blood was collected for measurement of serum T 4 and thyrotropin (TSH). All fetuses were frozen intact as described above. Frontal sections through the cortex and thalamus of one fetus from each dam were collected (Altman and Bayer, 1995) .
After in situ hybridization, the signal was measured over the cortex and thalamus of GD16 fetal brains using the thresholding f unction in which all pixels containing density values exceeding a minimum value were averaged over the specified brain area. The resulting values were averaged over four sections for each fetus, with one fetus per litter and four to five litters per treatment group. A two-way ANOVA, with main effects of MM I treatment and timing of acute T 4 exposure, was followed by Bonferroni's t test.
To confirm the in situ hybridization results, we performed Northern analysis on RNA extracted from fetal cortex derived from dams treated with either MM I alone or MM I plus T 4 . The cortex was dissected from one GD16 fetus per litter, derived from uninjected MM I-treated dams (n ϭ 4) and MM I-treated dams injected with T 4 at 9 P.M. on GD14 (n ϭ 5). RNA was extracted from these tissue pools as described above. Four replicates of total RNA from each pool (20 g RNA per lane) were electrophoresed with RNA molecular weight standards (Life Technologies, Gaithersburg, MD) on a 1.2% agarose/6.5% formaldehyde gel. RNA was transferred to a nylon Z eta-Probe membrane (Bio-Rad Laboratories, Hercules, CA) and cross-linked by baking. C yclophilin and NSP probes were generated by both random primer labeling and nick translation in the presence of 32 P-dC TP according to the manufacturer's instructions (Boehringer Mannheim, Indianapolis, I N). Both types of cyclophilin and NSP probes were mixed and hybridized simultaneously to ensure adequate detection of the target mRNA. Membranes were briefly prehybridized, hybridized at high stringency with 10 6 cpm probe/ 10 6 cpm probe/1 ml hybridization buffer, and washed according to manufacturer's instructions. The membranes were then apposed to a storage phosphor screen (Molecular Dynamics, Sunny vale, CA), scanned into a Storm 840 Phosphorimager at 200 m resolution, and evaluated with ImageQuant (Molecular Dynamics). The density of each band was quantified and normalized with respect to cyclophilin to control for loading variations. Student's t test was used to compare normalized band densities between the two RNA pools. In a separate experiment, serial dilutions of total RNA demonstrated a linear relationship between the amount of total RNA loaded and intensity of the cyclophilin signal between 5 and 20 g RNA (data not shown).
E xperiment III: Developmental pattern of NSP and Oct-1 e xpression in the brain. We initiated this study to define changes in NSP and Oct-1 expression during development to ensure that the pattern of expression observed in adults represents continuous expression from embryonic life. Nulliparous female Sprague Dawley rats (n ϭ 6; Z ivic Miller) were maintained on rat chow and unaltered drinking water ad libitum and mated as described above. Five dams (n ϭ 1 per GD) were decapitated at 12 P.M. on GD14, GD16, GD18, and GD21, and the fetuses were collected and sectioned as described in E xperiment II. The remaining dam carried the pregnancy to term. The resulting pups [n ϭ 1 per postnatal day (PN D)] were decapitated at 12 P.M. on PN D3, -6, -9, -11, -14, and -19, and the intact heads (PN D11 or earlier) or brains (PN D14 -PN D19) were frozen on pulverized dry ice and stored at Ϫ80°C. An adult male Sprague Dawley rat was used to determine the expression pattern in the adult brain. Coronal sections were collected through the brain at the level of the rostral dentate gyrus. E xperiment I V: Effect of thyroid hormone on NSP and Oct-1 e xpression in the adult brain. We tested whether NSP and Oct-1 expression is affected by thyroid status in adults because it allowed us to test the thyroid hormone responsiveness of these genes in the absence of the maternal system and provided information about the temporal window of sensitivity to thyroid hormone. We manipulated thyroid hormone status of adult male Sprague Dawley rats (n ϭ 23, 155-190 gm; Z ivic Miller), as described by Koller et al. (1987) . Each animal received a single intraperitoneal injection of either saline or 6-(n-propyl)-2-thiouracil (P TU; 1 mg /100 gm BW; Sigma) (Dyess et al., 1988) to block both thyroid hormone synthesis and the conversion of T 4 to triiodothyronine (T 3 ) by type I 5Ј-deiodinase (Chopra, 1996; Leonard and Koehrle, 1996) . P TU-treated animals (n ϭ 12) were maintained for 12 d after P TU treatment on 0.05% MM I in the drinking water, provided fresh daily, and at 9 A.M. they received daily subcutaneous injections of either T 3 (10 g /100 gm BW; Sigma; n ϭ 6) or 100 l saline/100 gm BW (n ϭ 6). The remaining rats (n ϭ 11, no P TU) were maintained on unaltered drinking water and at 9 A.M. received daily subcutaneous injections of either 10 g T 3 /100 gm BW (n ϭ 6) or 100 l saline/100 gm BW (n ϭ 5).
After treatment, animals were decapitated at 1 P.M., and trunk blood was collected for measurement of serum total T 3 , total T 4 , and TSH. Additionally, the relative abundance of the mRNA encoding thyrotropin releasing hormone (TRH) was measured in the hypothalamic paraventricular nucleus (PV N). Brains were collected and immediately frozen as described above. Coronal sections were collected through the brain at the level of the PV N (Paxinos and Watson, 1986, their Fig. 25 ) and through the cortex and hippocampus at the transition from the frontal cortex to the occipital cortex (Paxinos and Watson, 1986, their Figs. 31-33) . Sagittal sections were collected through the cerebellum (Paxinos and Watson, 1986, their Fig. 79) .
After in situ hybridization, the signal was measured over the PV N (only for TRH), cortex, dentate gyrus, CA1, CA2, CA3, and cerebellum. Signals in the cortex and hippocampus were measured without using thresholding, whereas measurements in the PV N and cerebellum were obtained using thresholding as described above. These values were averaged over four sections for each brain region, with five to six animals per treatment group. A two-way ANOVA, with main effects of MM I treatment and T 3 injection, was followed by Bonferroni's t test.
Radioimmunoassay. Total T 4 was measured according to the manufacturer's instructions using a T 4 RIA kit (IC N, Costa Mesa, CA). This assay was performed at 40% binding with detection limits of 10 -200 ng /ml and an intra-assay variation of 3.5%. Total T 3 was measured according to the manufacturer's instructions using a T 3 radioimmunoassay (RIA) kit (IC N). This assay was performed at 49% binding with detection limits of 0.25-8 ng /ml and an intra-assay variation of 4.4%. Serum levels of TSH were measured using 125 I-rat TSH (Covance Laboratories, Vienna, VA) and the double antibody National Institute of Diabetes and Digestive and K idney Diseases RIA reagents including RP-3 standards. This assay was performed at 25% binding with detection limits of 1-50 ng /ml and an intra-assay variation of 8.0%.
In situ hybridization. In all experiments, frozen tissues were sectioned at 12 m in a cryostat (Reichert-Jung Frigocut 2800N). Sections were thaw-mounted onto gelatin-coated microscope slides and stored at Ϫ80°C until hybridization. In situ hybridization was performed as described previously (Scott et al., 1998) , with two exceptions. First, the hybridization buffer also contained 0.1% sodium pyrophosphate. Second, the hybridization buffer contained 200 mM dithiothreitol rather than 50 mM.
Probes. cRNA probes were generated from cDNA constructs described in Table 2 . Transcription reactions were performed in the presence of 33 P-␣UTP (Andotek, Irvine, CA), as described previously (Scott et al., 1998) . In each case, the total concentration of UTP was held to 12 M, including 6 M 33 P-␣UTP. Autoradiography and signal quantitation. Slides were arranged in x-ray cassettes and apposed to BioMax film (Kodak), where the duration of exposure was dependent on the specific activity of the probe and the abundance of the target message.
14 C standards (American Radiolabeled Chemicals, St. L ouis, MO) were simultaneously apposed to the film to verif y that the film was not overexposed. Hybridization signal was analyzed as described previously (Scott et al., 1998 ) using a PowerC enter 150 Macintosh computer and the public domain N IH Image program (W. Rasband, National Institute of Mental Health). This system was interfaced with a Dage-MTI 72 series video camera equipped with a Nikon macro lens mounted onto a bellows system over a light box.
Statistical anal ysis. Outliers, defined as those values exceeding 1.5 interquartile ranges from the upper and lower quartiles, were eliminated using a box and whisker plot (Statistix, Analytical Software, Tallahassee, FL). A two-way ANOVA (Systat, Systat, Inc., Evanston, IL) was performed on the remaining values, with main effects described in the specific experiment. Post hoc tests of differences among individual means were performed using a Bonferroni's t test, in which the mean squared error term from the ANOVA table was used as a point estimate of the pooled variance. a The enzyme used for linearizing the plasmid and the polymerase used to produce the complementary (antisense) RNA probe. b The enzyme used for linearizing the plasmid and the polymerase used to produce the control (sense) RNA probe.
RESULTS

Experiment I: Identification of thyroid hormoneresponsive genes in the GD16 cortex
We manipulated maternal thyroid status before the onset of fetal thyroid function to ensure that maternal T 4 was the sole source of thyroid hormone to the fetus. Using differential display, we identified 11 putative thyroid hormone-responsive genes in the fetal cortex generated from eight RNAimage primer combinations (Table 1) . Seven of these genes appeared to be enhanced by T 4 , and four appeared to be suppressed by T 4 . Before sequencing these gene fragments, we performed in situ hybridization to determine whether their expression pattern overlapped with that of TR␣1 or TR␤1. Among the original 11 genes, we found that eight exhibited anatomical patterns of expression overlapping with that of TR␣1 or TR␤1 (Fig. 1 ), indicating that they may be directly regulated by thyroid hormone. We chose to further evaluate three of these genes, two whose sequences matched entries in GenBank ( (Wieczorek and Hughes, 1991; van de Velde et al., 1994b; Baka et al., 1996) and was suppressed by T 4 ; fragment 18C was identical to Oct-1 (J. N. Buskin, unpublished observations) and was enhanced by T 4 ; and fragment 6C did not match the sequence of any GenBank entry and was suppressed by T 4 .
Experiment II: Verification of maternal thyroid hormone effects on the expression of NSP, Oct-1, and 6C
We confirmed the efficacy of our thyroid hormone manipulation of pregnant female rats by measuring maternal serum total T 4 and TSH (Fig. 2) . Treatment with the goitrogen MMI significantly reduced circulating levels of maternal T 4 (F (1,34) ϭ 59.957; p Ͻ 0.001) and significantly elevated serum TSH (F (1,30) ϭ 50.983; p Ͻ 0.001). Treatment with thyroid hormone significantly elevated maternal serum T 4 (F (4,34) ϭ 11.776; p Ͻ 0.001) (Fig. 2) . A single injection of 1.25 g T 4 /100 gm BW transiently restored circulating T 4 to physiological levels and transiently suppressed TSH levels in hypothyroid dams, as predicted. However, physiological levels of T 4 were restored only 12 hr after T 4 injection in hypothyroid dams, but remained elevated in euthyroid dams for at least 24 hr (Fig. 2) . Likewise, TSH suppression was evident for a shorter duration in hypothyroid dams. These data are consistent with previous work showing that thyroid hormone is cleared from the serum of hypothyroid dams more rapidly than from that of euthyroid dams (Versloot et al., 1998) . We measured the effects of maternal thyroid hormone manipulation on gene expression in the fetal brain using in situ hybridization because this approach allowed us to evaluate the potential site-specific effects of thyroid hormone on NSP, Oct-1, and 6C expression. Quantitative analysis of film autoradiograms after in situ hybridization revealed that both MMI (F (1,31) ϭ 9.851; p Ͻ 0.004) and maternal thyroid hormone (F (4,31) ϭ5.146; p Ͻ 0.003) significantly affected NSP expression in the GD16 cortex (Fig. 3) . Maternal thyroid hormone exposure significantly decreased NSP mRNA in the cortex of hypothyroid animals 36 hr after T 4 injection (9 P.M. on GD14). In contrast, thyroid hormone exposure significantly increased Oct-1 mRNA in the cortex of euthyroid animals 12 and 24 hr after T 4 injection (9 P.M. and 9 A.M., respectively, on GD15). These results are consistent with those of the original differential display where NSP expression was decreased by maternal thyroid hormone and Oct-1 expression was increased by maternal thyroid hormone. The expression of neither NSP nor Oct-1 was affected by thyroid hormone in the thalamus (data not shown). Additionally, 6C was not affected by thyroid hormone in either the cortex or the thalamus, suggesting that it was falsely identified as being thyroid hormone responsive in the differential display.
Previous work has shown that two mRNAs are transcribed from the NSP gene, a 1.5 kb transcript (NSP-C) and a 3.5 kb transcript (NSP-A) (Ninkina et al., 1997; Roebroek et al., 1998) . Because these transcripts have a common 3Ј end identical to the NSP fragment amplified in the original differential display, our in situ hybridization probe hybridized to both transcripts. Therefore, we performed Northern analysis to determine whether both NSP transcripts are affected by maternal thyroid hormone. Northern analysis revealed that our probe hybridized to the predicted 1.5 and 3.5 kb transcripts (Fig. 4 A) . Expression of the 3.5 kb NSP-A transcript was significantly decreased (30.7 Ϯ 13.0%) in fetuses derived from hypothyroid dams treated with T 4 (Fig. 4 B) . In contrast, expression of the 1.5 kb NSP-C transcript was unaffected by acute maternal thyroid hormone manipulation.
Experiment III: Developmental pattern of NSP and Oct-1 expression
After the initial observation that both NSP and Oct-1 were regulated by thyroid hormone in the GD16 cortex, we characterized the distribution and relative abundance of these mRNAs during development. We found that NSP expression was restricted to the nervous system at all times (Fig. 5) c Significantly different from hypothyroid dams with identical timing of acute T 4 treatment ( p Ͻ 0.05). Note: Serum hormone levels below detection limit were assigned the value of the detection limit (indicated by dashed line) for statistical purposes.
mRNA was more abundant during the fetal and neonatal period but became less abundant from approximately PND14 through adulthood. Regional differences in NSP expression were apparent throughout brain development. For example, NSP expression was predominant in the ventromedial hypothalamic nucleus beginning around the time of birth and persisting into adulthood. The hippocampus, medial habenular nucleus, and amygdala were also intensely labeled. The corpus callosum and other myelinated fiber bundles were never labeled.
Oct-1 mRNA was expressed both within the brain and outside the nervous system (Fig. 6) . Oct-1 expression was predominant in the ventricular zone of the cortex of fetal brains. Regional differences in Oct-1 expression levels were apparent throughout brain development. For example, Oct-1 expression was abundantly expressed in the thalamus from approximately GD16 until PND14. As development proceeded, Oct-1 expression became less robust and more spatially restricted, although expression was retained in the hippocampus.
Experiment IV: Effect of thyroid hormone on NSP and Oct-1 expression in the adult brain
The developmental study demonstrated that NSP and Oct-1 were continually expressed in the cortex from fetal life to adulthood. Therefore, we evaluated the effect of thyroid status on the expression of these genes in the adult brain to determine whether these genes retained their responsiveness to thyroid hormone. We confirmed the efficacy of our thyroid hormone manipulations of adult male rats by measuring serum T 3 , T 4 , and TSH and by measuring TRH mRNA in the PVN of the hypothalamus, which is known to be suppressed by thyroid hormone (Koller et al., 1987 (Koller et al., 1987; Dyess et al., 1988; Zoeller et al., 1988) . Combined PTU and MMI treatment significantly elevated NSP mRNA in the dentate gyrus (F (1,17) ϭ 6.719; p Ͻ 0.02) and CA1 subfield of Ammon's horn (F (1,18) ϭ 4.777; p Ͻ 0.05) (Table  4) . Additionally, T 3 treatment significantly decreased NSP mRNA in the dentate gyrus (F (1,17) ϭ 6.682; p Ͻ 0.02). NSP mRNA levels in the cortex, CA2, and CA3 subfields, and cerebellum were unaffected by treatments. In contrast, T 3 treatment significantly reduced Oct-1 mRNA in the cortex (F (1,19) (Table 4) . Oct-1 mRNA levels in the CA1 subfield and cerebellum were unaffected by treatments.
DISCUSSION
The present studies are the first to demonstrate that thyroid hormone can affect gene expression in the fetal rat brain. Moreover, because we manipulated thyroid status of pregnant rats before the onset of fetal thyroid function, our data clearly demonstrate that thyroid hormone specifically of maternal origin affects the expression of these genes. Considering recent observations that maternal thyroid hormone reaches the fetus (Vulsma et al., 1989; Contempre et al., 1993) and that children born to pregnant women with untreated hypothyroidism exhibit measurable neurological deficits (Haddow et al., 1999; Pop et al., 1999) , our data strongly indicate that thyroid hormone of maternal origin affects fetal brain development by regulating the expression of specific genes.
Using differential display, we identified 11 putative thyroid hormone-responsive genes in the fetal brain using only eight primer pairs. Thus, a large number of genes expressed in the fetal brain may be affected by maternal thyroid hormone. Differential display is known to generate false-positives, as do other "subtrac- Figure 3 . Effect of thyroid hormone manipulation on gene expression in the GD16 fetus (Experiment II). Quantitative analysis of film autoradiograms after in situ hybridization for NSP, Oct-1, and 6C are described in Materials and Methods. Bars represent mean Ϯ SEM of the film density (converted to % controls Ϯ CV) over the cortex, with number of dams per group noted within each bar. All animals were killed at 9 A.M. (0900) on GD16. Groups differed in the timing of T 4 injection as shown below the ordinate. Open bars, Euthyroid dams (no MMI); closed bars, hypothyroid dams (MMI).
a Significantly different from hypothyroid dams receiving no injection ( p Ͻ 0.05).
b Significantly different from hypothyroid dams with identical timing of acute T 4 treatment ( p Ͻ 0.05).
tive" hybridization methods designed to identify differentially expressed genes (Wan and Erlander, 1997; Ledakis et al., 1998) . However, only one of three genes chosen for further analysis was a false-positive. This success rate may have been caused in part by the anatomical screen used to determine whether genes identified by differential display were expressed in brain areas containing TRs. Although nearly all of the gene fragments generated from the differential display were selectively expressed in brain areas and in organs that are responsive to thyroid hormone (Fig. 1) , the genes chosen for further analysis were the most abundant and selectively expressed in TR-containing brain regions.
In principle, thyroid hormone of maternal origin could affect the expression of genes in the fetal brain by a direct action or by various indirect actions. However, several features of the present Figure 4 . Effect of thyroid hormone manipulation on the expression of NSP variants using quantitative Northern analysis (Experiment II). A, Phosphorimage of Northern blot in which 20 g total RNA was hybridized with 32 Plabeled NSP cDNA.
32 P-labeled cyclophilin cDNA was hybridized simultaneously to control for loading variations. RNA was isolated from GD16 fetuses derived from hypothyroid dams receiving either no injection (Ϫ) or a single T 4 injection at 9 P.M. on GD14 (ϩ). Each sample corresponds to RNA pooled from four or five animals. Positions of the molecular weight standards and the 18S and 28S ribosomal RNAs are indicated. B, Quantification of band density shown in A using ImageQuant software. NSP-A mRNA was decreased after acute maternal T 4 exposure. Bars represent mean band density Ϯ SEM (converted to % total cyclophilin).
a Transcript of 3.5 kb hybridized to NSP probe, corresponding to NSP-A. b Transcript of 3.4 kb hybridized to cyclophilin probe.
c Transcript of 1.5 kb hybridized to NSP probe, corresponding to NSP-C. d Transcript of 0.9 kb hybridized to cyclophilin probe. *Significantly different from hypothyroid dams receiving no injection ( p Ͻ 0.05). results suggest that maternal thyroid hormone affects gene expression by a direct action. First, the dose of thyroid hormone given to the dam did not produce supraphysiological levels of T 4 in maternal blood. Therefore, the observed effects were not caused by thyrotoxic effects of thyroid hormone. Second, the single injection of T 4 produced rapid, transient, and selective effects on gene expression in the fetal brain. The abundance of the NSP mRNA was suppressed within 36 hr, whereas that of Oct-1 mRNA was elevated within 12 hr. These effects were observed only in the cortex, not in the thalamus, and 6C was unaffected in both brain regions. In contrast, nonspecific or metabolic effects of thyroid hormone would more likely produce similar effects on the abundance of various genes and would not likely be limited to specific brain regions. Finally, we clearly demonstrated that NSP and Oct-1 expression can be regulated by T 3 in the adult brain. Therefore, the effects of thyroid hormone on the expression of these two genes is not dependent on the maternal system or on injecting T 4 . Taken together, these data provide strong support for the concept that thyroid hormone of maternal origin can directly affect the expression of genes in the fetal brain.
Considering the evidence that thyroid hormone exerts a direct action on the expression of NSP and Oct-1, it was surprising that the administration of MMI did not affect their expression in the SEM (n) . TRH values represent mean Ϯ SEM (n) of film density (converted to % control Ϯ CV) over the PVN. * Significantly different from control euthyroid rats receiving saline injections ( p Ͻ 0.05). ** Significantly different from control euthyroid rats receiving saline injections ( p Ͻ 0.01). UD, Undetectable. Serum hormone levels were assigned the value of the lower assay detection limit for statistical purposes. fetal brain, as measured by in situ hybridization. In the case of NSP, this may be related to the transcript-specific regulation by thyroid hormone. Specifically, the NSP fragment amplified in the differential display hybridized to two transcripts, a 1.5 kb transcript designated NSP-C and a 3.5 kb transcript designated NSP-A (van de Velde et al., 1994b; Ninkina et al., 1997) . Northern analysis of RNA extracted from fetuses derived from MMItreated dams showed that T 4 suppressed only NSP-A mRNA. Because NSP-A expression is much lower than that of NSP-C but our probe hybridized to both transcripts, we may not have detected the selective effects of MMI on NSP-A expression. Evaluation of the same tissues with probes specific for NSP-A and NSP-C has confirmed this interpretation (A. L. S. Dowling, unpublished observations). It must be noted, however, that hypothyroxinemia itself induces a number of compensatory mechanisms that ameliorate the consequences of low thyroid hormone levels in the fetal brain. These compensatory mechanisms may account for the unremarkable effects of MMI on the expression of NSP and Oct-1. For example, thyroid hormone uptake into tissues is enhanced in hypothyroid animals (Everts et al., 1994a (Everts et al., ,b, 1995 Moreau et al., 1999) , as is the conversion of T 4 to T 3 in fetal tissue (Ruiz de Ona et al., 1988; Calvo et al., 1990) . We observed the effects of these compensatory mechanisms in that MMI-treated dams exhibited elevated T 4 and suppressed TSH for a shorter duration after a single injection of T 4 . In the original differential display, we eliminated the potential confounding effects of compensatory mechanisms by comparing RNA pools extracted from fetuses derived from thyroidectomized dams only. Therefore, conditions under which genes were identified in the differential display represented only a subset of conditions tested in our follow-up studies.
The functional characteristics of NSP and Oct-1 may provide insight into thyroid hormone effects on the prenatal brain. NSP is a neuron-specific protein (Wieczorek and Hughes, 1991) integrated into the endoplasmic reticulum (van de Velde et al., 1994a,b) , and its expression is correlated with neuronal differentiation (Hens et al., 1998) . NSP mRNA is localized to the axonal pole of neuronal cell bodies (Baka et al., 1996; Ninkina et al., 1997) and may play a role in protein packaging and/or trafficking (Senden et al., 1996) . As shown here, expression of NSP appears to be regionally and developmentally regulated. Overall, the abundance of NSP mRNA declines during development in all areas studied. However, NSP expression is robust in both the hippocampus and the cortex throughout development. In these areas, NSP expression is consistently high from GD14, the earliest time evaluated, to adulthood. At early developmental stages, NSP mRNA appears to be more abundant in the intermediate zone of the cortex and less abundant in the periventricular zone. As the brain matures and cortical layers develop, NSP expression in the cortex takes on a laminar appearance. The regulation of NSP-A by thyroid hormone during early cortical development and its differential expression in the intermediate zone of the GD16 cortex supports the concept that NSP is involved in neuronal differentiation and that this role is modulated by thyroid hormone. Oct-1 is a POU-domain protein (He et al., 1989; Treacy and Rosenfeld, 1992) , named for the initial genes identified within this family, Pit-1, Oct-1/2, and Unc-86. Downregulation of Oct-1 expression is associated with cell cycle arrest and differentiation (Lakin et al., 1995) , suggesting a role for Oct-1 in proliferation. Like NSP, the expression of Oct-1 appeared to be regionally and developmentally regulated, and the abundance of Oct-1 mRNA declined during brain development. In contrast to NSP, Oct-1 mRNA was detected both within and outside the nervous system and in early development was selectively expressed in the periventricular zone of the cortex. This zone contains proliferating neurons (Caviness et al., 1995) that express only TR␤1 (Bradley et al., 1992) . Because Oct-1 has been shown to stimulate TR␤1 expression (Nagasawa et al., 1997) , thyroid hormone may act through TR␤1 to enhance Oct-1 expression and maintain TR␤1 expression in these proliferating neurons. Both TR␤1 (Bradley et al., 1992) and Oct-1 expression diminish once these neurons leave the ventricular zone and begin to differentiate.
It is interesting to note that both NSP and Oct-1 expression retained their responsiveness to thyroid hormone in the adult brain. However, NSP expression was affected by thyroid hormone only in the hippocampus where it was enhanced by hypothyroidism. In contrast, Oct-1 expression was suppressed by thyroid hormone in both the cortex and the hippocampus. Considering that the specific effect of thyroid hormone on gene expression may depend on the cofactor recruited to the hormone receptor complex (Koenig, 1998) , the change in direction of regulation of Oct-1 by thyroid hormone during development may be related to developmental changes in coactivator and corepressor expression. In addition, the retention of thyroid hormone responsiveness in adulthood demonstrates that these genes do not exhibit a "critical period" of thyroid hormone sensitivity. Finally, the observation that chemical thyroidectomy does not fully abolish Oct-1 expression suggests that NSP and Oct-1 expression are not fully dependent on thyroid status, but their expression is modulated nonetheless.
In conclusion, these studies show that thyroid hormone of maternal origin can selectively regulate the expression of genes in the fetal brain. Furthermore, these genes may retain their sensitivity to thyroid hormone in the adult brain. One can reasonably speculate that maternal thyroid hormone could influence gene expression in the fetal brain by a direct mechanism and various indirect mechanisms. Our data support the concept that thyroid hormone regulates the expression of NSP and Oct-1 by a direct action. Our use of differential display in combination with an acute administration of a physiological dose of thyroid hormone may have enhanced our ability to identify genes directly regulated by thyroid hormone.
